BLAU3.SA SAO
Blau Farmacêutica S.A.
1W: +6.2%
1M: +11.5%
3M: +7.3%
YTD: +10.1%
1Y: -4.8%
3Y: -30.5%
5Y: -72.0%
R$10.84 ($2.07)
+0.10 (+0.93%)
Weekly Expected Move ±3.4%
R$10
R$10
R$11
R$11
R$12
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$3.6B
+6.5% ▲
5Y CAGR: +23.4%
Total Liabilities
$1.4B
+9.4% ▲
5Y CAGR: +5.6%
Shareholders Equity
$2.3B
+5.0% ▲
5Y CAGR: +59.3%
Cash & Investments
$615M
+24.8% ▲
5Y CAGR: +23.5%
Total Debt
$599M
+7.2% ▲
5Y CAGR: -2.8%
Net Debt
$554M
+5.3% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $52M | $14M | $31M | $33M | $46M |
| Short-Term Investments | $871M | $630M | $376M | $460M | $569M |
| Cash & ST Investments | $923M | $644M | $407M | $493M | $615M |
| Net Receivables | $332M | $421M | $454M | $477M | $588M |
| Inventory | $417M | $569M | $629M | $606M | $694M |
| Other Current Assets | $25M | $45M | $64M | $100M | $0 |
| Total Current Assets | $1.7B | $1.7B | $1.6B | $1.7B | $1.9B |
| Property, Plant & Equip. | $372M | $542M | $739M | $845M | $1.0B |
| Goodwill & Intangibles | $149M | $160M | $176M | $488M | $617M |
| Long-Term Investments | $43K | $0 | $265M | $293M | $31M |
| Other Non-Current Assets | $111M | $119M | $238M | $25M | $654K |
| Total Non-Current Assets | $632M | $821M | $1.5B | $1.7B | $1.7B |
| Total Assets | $2.3B | $2.5B | $3.1B | $3.4B | $3.6B |
| — Liabilities — | |||||
| Accounts Payable | $116M | $164M | $179M | $286M | $266M |
| Short-Term Debt | $92M | $80M | $70M | $67M | $286M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $58M | $48M | $35M | $95M | $48M |
| Total Current Liabilities | $343M | $371M | $336M | $538M | $768M |
| Long-Term Debt | $273M | $200M | $500M | $450M | $283M |
| Other Non-Current Liab. | $45M | $42M | $63M | $67M | $75M |
| Total Non-Current Liabilities | $350M | $310M | $722M | $723M | $611M |
| Total Liabilities | $693M | $681M | $1.1B | $1.3B | $1.4B |
| — Equity — | |||||
| Common Stock | $1.3B | $1.3B | $1.3B | $1.3B | $1.7B |
| Retained Earnings | $325M | $563M | $744M | $899M | $612M |
| Accumulated OCI | -$5M | -$17M | -$17M | -$9M | -$14M |
| Total Stockholders Equity | $1.6B | $1.8B | $2.0B | $2.2B | $2.3B |
| Total Liabilities & Equity | $2.3B | $2.5B | $3.1B | $3.4B | $3.6B |
| — Key Metrics — | |||||
| Total Debt | $375M | $312M | $609M | $559M | $599M |
| Net Debt | $323M | $298M | $577M | $526M | $554M |
| Total Investments | $871M | $630M | $641M | $753M | $601M |